CRNX

NEUTRALM&A

Crinetics Pharmaceuticals, Inc.

2026-08-26

Price

$84.84

-0.02%

This is the 2026-08-26 snapshot — the signals and analysis for CRNX as of this single trading day.

View full CRNX research hub →

Score9.8Priority

Signals7/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume0.2xvs 20d avg

Analysis

The primary driver behind Crinetics Pharmaceuticals' (CRNX) price action is its pending $85.00 per share all-cash acquisition by Vertex Pharmaceuticals, which is expected to close in Q3 2026. This definitive M&A catalyst perfectly explains the stock's ultra-low 2.4% annualized volatility and the QUIET_STORM technical signal, as shares are pinned at $84.84 in a classic merger arbitrage setup. Furthermore, the highly supportive RISK_ON macro regime and exceptionally tight high-yield credit spreads (0.81%) provide high conviction that broader market liquidity conditions will not jeopardize the deal's final completion.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKSELLER FATIGUEWEAK FINISH

Key Takeaways

Actionable Thesis: CRNX is a pure merger arbitrage hold, trading at a fractional discount ($84.84) to the $85.00 all-cash acquisition price from Vertex Pharmaceuticals.
Key Risk: Deal collapse due to unforeseen FTC/regulatory antitrust hurdles is the only major risk, as macro financing risks are neutralized by tight credit spreads.
What to Watch: Monitor for the official acquisition closing announcements expected in Q3 2026, which will finalize the payout and delist the equity.

← Back to 2026-08-26 View Full CRNX History →Yahoo Finance &nearr;